Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Powers

Showing results (71-80 of 82) with videos related to

Pageof 9
Sort By:
Archives of Suicide Research : Official Journal of the International Academy for Suicide Research|August 28, 2024
Development and Validation of Electronic Health Record Measures of Safety Planning Practices as Part of Zero Suicide ImplementationJennifer M Boggs, Bobbi Jo H Yarborough, Gregory Clarke, et al.
Journal of Medicinal Chemistry|January 27, 2007
Alkynylpyrimidine amide derivatives as potent, selective, and orally active inhibitors of Tie-2 kinaseVictor J Cee, Brian K Albrecht, Stephanie Geuns-Meyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2008
CS1, a potential new therapeutic antibody target for the treatment of multiple myelomaEric D Hsi, Roxanne Steinle, Balaji Balasa, et al.
Frontiers in Pharmacology|March 7, 2019
Drug Repurposing: The Anthelmintics Niclosamide and Nitazoxanide Are Potent TMEM16A Antagonists That Fully Bronchodilate AirwaysKent Miner, Katja Labitzke, Benxian Liu, et al.
Journal of the American Heart Association|March 28, 2018
Device Therapies Among Patients Receiving Primary Prevention Implantable Cardioverter-Defibrillators in the Cardiovascular Research NetworkRobert T Greenlee, Alan S Go, Pamela N Peterson, et al.
Journal of Medicinal Chemistry|February 19, 2008
Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activityMatthew W Martin, John Newcomb, Joseph J Nunes, et al.
Journal of Medicinal Chemistry|June 11, 2016
Discovery and Optimization of Quinazolinone-pyrrolopyrrolones as Potent and Orally Bioavailable Pan-Pim Kinase InhibitorsLiping H Pettus, Kristin L Andrews, Shon K Booker, et al.
Journal of Medicinal Chemistry|January 10, 2019
Discovery of ( R)-8-(6-Methyl-4-oxo-1,4,5,6-tetrahydropyrrolo[3,4- b]pyrrol-2-yl)-3-(1-methylcyclopropyl)-2-((1-methylcyclopropyl)amino)quinazolin-4(3 H)-one, a Potent and Selective Pim-1/2 Kinase Inhibitor for Hematological MalignanciesHui-Ling Wang, Kristin L Andrews, Shon K Booker, et al.
Faraday Discussions|July 24, 2023
Make - underpinning concepts of the synthesis of systems where non-covalent interactions are important: general discussionTorsten Beweries, Michael R Buchmeiser, Frances E Bugden, et al.
Journal of Medicinal Chemistry|March 7, 2008
Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activationErin F DiMauro, John Newcomb, Joseph J Nunes, et al.
Pageof 9

Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
Archives of Suicide Research : Official Journal of the International Academy for Suicide Research|August 28, 2024
Development and Validation of Electronic Health Record Measures of Safety Planning Practices as Part of Zero Suicide ImplementationJennifer M Boggs, Bobbi Jo H Yarborough, Gregory Clarke, et al.
Journal of Medicinal Chemistry|January 27, 2007
Alkynylpyrimidine amide derivatives as potent, selective, and orally active inhibitors of Tie-2 kinaseVictor J Cee, Brian K Albrecht, Stephanie Geuns-Meyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2008
CS1, a potential new therapeutic antibody target for the treatment of multiple myelomaEric D Hsi, Roxanne Steinle, Balaji Balasa, et al.
Frontiers in Pharmacology|March 7, 2019
Drug Repurposing: The Anthelmintics Niclosamide and Nitazoxanide Are Potent TMEM16A Antagonists That Fully Bronchodilate AirwaysKent Miner, Katja Labitzke, Benxian Liu, et al.
Journal of the American Heart Association|March 28, 2018
Device Therapies Among Patients Receiving Primary Prevention Implantable Cardioverter-Defibrillators in the Cardiovascular Research NetworkRobert T Greenlee, Alan S Go, Pamela N Peterson, et al.
Journal of Medicinal Chemistry|February 19, 2008
Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activityMatthew W Martin, John Newcomb, Joseph J Nunes, et al.
Journal of Medicinal Chemistry|June 11, 2016
Discovery and Optimization of Quinazolinone-pyrrolopyrrolones as Potent and Orally Bioavailable Pan-Pim Kinase InhibitorsLiping H Pettus, Kristin L Andrews, Shon K Booker, et al.
Journal of Medicinal Chemistry|January 10, 2019
Discovery of ( R)-8-(6-Methyl-4-oxo-1,4,5,6-tetrahydropyrrolo[3,4- b]pyrrol-2-yl)-3-(1-methylcyclopropyl)-2-((1-methylcyclopropyl)amino)quinazolin-4(3 H)-one, a Potent and Selective Pim-1/2 Kinase Inhibitor for Hematological MalignanciesHui-Ling Wang, Kristin L Andrews, Shon K Booker, et al.
Faraday Discussions|July 24, 2023
Make - underpinning concepts of the synthesis of systems where non-covalent interactions are important: general discussionTorsten Beweries, Michael R Buchmeiser, Frances E Bugden, et al.
Journal of Medicinal Chemistry|March 7, 2008
Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activationErin F DiMauro, John Newcomb, Joseph J Nunes, et al.
Pageof 9